Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
ONVO

Organovo Holdings Inc

ONVO

1.18USD0.00 (0.00%)Delayed as of 28 Nov 2023, 12:45 pm
Watchlist

Market Summary

USD1.180.00
Delayedas of 28 Nov 2023, 12:45 pm
0.00%

ONVO Stock Price

View Fullscreen

ONVO RSI Chart

ONVO Valuation

Market Cap

10.3M

Price/Earnings (Trailing)

-0.55

Price/Sales (Trailing)

27.96

Price/Free Cashflow

-0.62

ONVO Price/Sales (Trailing)

ONVO Profitability

Free Cashflow Yield

-160.88%

ONVO Fundamentals

ONVO Revenue

Revenue (TTM)

368.0K

Revenue Y/Y

-100%

Revenue Q/Q

-100%

ONVO Earnings

Earnings (TTM)

-18.7M

Earnings Y/Y

-20.26%

Earnings Q/Q

0.84%

Price Action

52 Week Range

1.003.40
(Low)(High)

Last 7 days

-7.8%

Last 30 days

8.3%

Last 90 days

-1.7%

Trailing 12 Months

-21.8%

How does ONVO drawdown profile look like?

ONVO Financial Health

ONVO Investor Care

Shares Dilution (1Y)

0.07%

Diluted EPS (TTM)

-2.15

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023370.0K445.0K368.0K0
202201.2M935.0K652.5K
20210000
20202.2M000
20193.1M3.1M3.4M2.9M
20184.6M4.3M3.9M3.5M
20174.2M4.3M4.3M4.3M
20161.5M2.1M3.1M4.0M
2015571.0K778.0K1.0M1.2M
2014379.0K372.0K399.0K419.0K
20131.3M1.1M693.0K479.0K
2012564.9K650.6K887.6K1.2M
2011513.3K423.6K631.7K645.7K
2010000603.0K
Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for ONVO

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 17, 2023
joshi vaidehi
acquired
-
-
19,607
-
Nov 17, 2023
gobel david
acquired
-
-
19,607
-
Nov 17, 2023
milhous alison tjosvold
acquired
-
-
19,607
-
Nov 17, 2023
cohen douglas jay
acquired
-
-
19,607
-
Nov 17, 2023
murphy keith
acquired
-
-
19,607
executive chairman
Nov 17, 2023
stern adam k
acquired
-
-
19,607
-
Nov 15, 2023
gobel david
sold
-31,749
1.6193
-19,607
-
Nov 10, 2022
gobel david
acquired
-
-
19,607
-
Nov 10, 2022
stern adam k
acquired
-
-
19,607
-
Nov 10, 2022
murphy keith
acquired
-
-
19,607
executive chairman

1–10 of 43

Which funds bought or sold ONVO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Nov 15, 2023
MORGAN STANLEY
reduced
-29.46
-44,594
48,647
 -%
Nov 15, 2023
HARBOUR INVESTMENTS, INC.
unchanged
-
-6.00
16.00
 -%
Nov 14, 2023
Credit Agricole S A
unchanged
-
-44.00
125
 -%
Nov 14, 2023
RENAISSANCE TECHNOLOGIES LLC
reduced
-16.43
-85,000
136,000
 -%
Nov 14, 2023
JPMORGAN CHASE & CO
added
25.00
-7.00
61.00
 -%
Nov 14, 2023
VANGUARD GROUP INC
reduced
-1.2
-128,871
349,780
 -%
Nov 14, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP
reduced
-74.11
-56,759
13,048
 -%
Nov 14, 2023
Tower Research Capital LLC (TRC)
reduced
-16.84
-4,329
6,918
 -%
Nov 14, 2023
NewEdge Advisors, LLC
reduced
-50.00
-213
125
 -%
Nov 14, 2023
Coppell Advisory Solutions LLC
sold off
-100
-215
-
 -%

1–10 of 38

Latest Funds Activity

Are funds buying ONVO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ONVO
No. of Funds

Schedule 13G FIlings of Organovo Holdings Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 03, 2023
sumitomo mitsui trust holdings, inc.
5.21%
454,752
SC 13G/A
Feb 14, 2022
nikko asset management americas, inc.
5.50%
478,570
SC 13G/A
Feb 04, 2022
sumitomo mitsui trust holdings, inc.
5.49%
478,570
SC 13G/A
Mar 10, 2021
ark investment management llc
9.48%
674,454
SC 13G/A
Feb 16, 2021
ark investment management llc
20.86%
1,404,620
SC 13G/A
Feb 11, 2021
nikko asset management americas, inc.
7.11%
478,570
SC 13G/A
Feb 11, 2021
renaissance technologies llc
5.36%
381,353
SC 13G/A
Feb 05, 2021
sumitomo mitsui trust holdings, inc.
7.11%
478,570
SC 13G/A
Oct 09, 2020
ark investment management llc
21.78%
1,422,394
SC 13G/A
Feb 14, 2020
ark investment management llc
14.95%
19,499,439
SC 13G/A

Recent SEC filings of Organovo Holdings Inc

View All Filings
Date Filed Form Type Document
Nov 17, 2023
4
Insider Trading
Nov 17, 2023
4
Insider Trading
Nov 17, 2023
4
Insider Trading
Nov 17, 2023
4
Insider Trading
Nov 17, 2023
4
Insider Trading
Nov 17, 2023
4
Insider Trading
Nov 15, 2023
144
Notice of Insider Sale Intent
Nov 09, 2023
10-Q
Quarterly Report
Nov 03, 2023
8-K
Current Report
Sep 22, 2023
8-K/A
Current Report

Peers (Alternatives to Organovo Holdings Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
HILS
32.8B
-
 14.55% 467931.97%
-3.8K
218.4K
 - -102.45%
MRNA
29.6B
10.7B
 8.07% -55.95%
-8.54
2.78
 -53.67% -129.46%
ALNY
20.0B
1.7B
 4.90% -25.16%
-39.17
11.59
 79.37% 56.87%
BMRN
16.7B
2.3B
 9.83% -8.58%
113.5
7.22
 15.05% 75.21%
INCY
11.8B
3.6B
 0.63% -32.44%
27.88
3.28
 8.35% -51.49%
MID-CAP
APLS
5.7B
272.9M
 1.64% -5.18%
-9.43
20.95
 141.38% 4.43%
BBIO
5.2B
-
 21.89% 247.20%
-8.88
48.33
 54.84% -12.96%
ACAD
3.6B
631.9M
 1.65% 46.39%
-24.37
5.74
 23.54% 31.53%
AXSM
3.1B
223.4M
 6.77% 16.65%
-15.53
14.03
 - -26.24%
ARWR
3.1B
256.2M
 21.69% -2.64%
-16.98
12
 2.51% -17.66%
SMALL-CAP
CPRX
1.5B
348.4M
 17.40% -16.91%
24.23
4.31
 81.69% -7.29%
NVAX
648.3M
1.0B
 -14.02% -66.99%
-1.18
0.62
 -43.15% 58.48%
INO
108.4M
6.4M
 10.81% -79.60%
-0.66
16.83
 -44.11% 50.48%
CRBP
18.7M
-
 -19.00% 3569.57%
-0.39
-
 - -13.74%
IBIO
8.0M
-
 - -82.21%
-0.12
-
 - -29.23%

Organovo Holdings Inc News

Latest updates
Clayton County Register • 26 Nov 2023 • 11:42 am • 2 days ago
Onvo Stock
Stocks Register • 20 Nov 2023 • 03:32 pm • 8 days ago
Organovo Holdings Inc (NASDAQ: ONVO) Has Not A Good News ...
Defense World • 20 Nov 2023 • 10:21 am • 8 days ago
Insider Selling: Organovo Holdings, Inc. (NASDAQ:ONVO) Director ...
InvestorsObserver • 17 Nov 2023 • 04:12 pm • 11 days ago
Should You Accumulate Organovo Holdings Inc (ONVO) Stock Friday?
InvestorsObserver • 07 Nov 2023 • 08:00 am • 21 days ago
Organovo Holdings Inc (ONVO) Stock: What Does the Chart Say Tuesday?
Nasdaq • 07 Nov 2023 • 08:00 am • 21 days ago
Pre-market Movers: CREV, VTYX, ALTO, TMDX, LIFW…
Yahoo Finance • 08 Sep 2023 • 07:00 am • 2 months ago
Organovo to Participate in the H.C. Wainwright Global Investment Conference
Yahoo Finance • 23 Aug 2023 • 07:00 am • 3 months ago
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
Seeking Alpha • 29 Jun 2023 • 07:00 am • 5 months ago
Evelo Biosciences stock plummets on reverse stock split
Yahoo Finance • 25 May 2023 • 07:00 am • 6 months ago
Cathie Wood is Selling These 12 Stocks in 2023
Simply Wall St • 10 Feb 2023 • 08:00 am • 9 months ago
Is Organovo Holdings (NASDAQ:ONVO) In A Good Position To Invest In Growth?
Value the Markets • 08 Nov 2022 • 08:00 am • 12 months ago
Spatial Computing – the future of technology
Seeking Alpha • 12 Sep 2022 • 07:00 am • 14 months ago
A $10 Million Loss? Never Sell (Buyandhold 2012) Vs. Selectively Sell
Seeking Alpha • 03 May 2022 • 07:00 am • 19 months ago
Heat Biologics completes name change to NightHawk Biosciences
Seeking Alpha • 28 May 2021 • 07:00 am • 2 years ago
Organovo: New Strategy Targeting Internal Pipeline Development ...

Financials for Organovo Holdings Inc

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-100.0%-75.0016213177.00-----------2981,230668680779
Costs and Expenses-3.6%4,1154,270--3,4313,239----2,5592,5982,4928,9502,7862,8935,5328,0577,1897,8427,305
Operating Expenses----3,4903,4313,239--3,5003,5072,559-2,4928,950-------
  S&GA Expenses6.8%2,7802,6042,4922,3052,2002,2192,278-2,5742,8281,9791,9252,0908,9222,7863,0225,3746,3483,3153,3373,387
  R&D Expenses-19.9%1,3351,6665,4491,1851,2311,0201,135-92667958067340228.00--1291451,4453,8234,4043,782
EBITDA Margin---------0.00*-0.01*-0.03*-0.04*-0.04*0.30*0.37*0.46*0.41*0.20*0.25*0.28*-
Income Taxes-100.0%-2.00---2.00--2.00-----2.00--2.00---
EBT Margin----------0.06*-0.06*-0.06*-0.06*-0.06*-0.06*-0.06*-0.06*-0.05*-0.04*-0.04*-0.04*-
Net Income0.8%-3,994-4,028-7,459-3,264-3,321-3,215-1,911--3,500-3,505-2,532-2,596-2,511-8,950-2,769-2,723-3,370-6,294-6,323-6,983-6,399
Net Income Margin------38.79*--7.63*-----7.66*-7.72*-8.11*-6.90*-8.52*-7.99*-7.74*-8.32*-8.62*-7.71*
Free Cashflow-----3,141-2,319-2,488-1,594--3,445-2,216-1,607-2,225-1,785-7,148-2,570-3,209-583-5,155---
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-24.4%11,16114,75620,31325,07927,91030,54633,29635,09535,88138,29439,91721,58120,64425,62128,44131,31237,77143,45140,62339,68542,625
  Current Assets-29.1%8,29611,69517,04821,61424,35726,90929,53331,17134,30336,65838,39820,09919,48525,50128,31831,10632,71437,35638,57437,47140,117
    Cash Equivalents-29.6%7,60010,80015,30120,19613,26515,56828,67530,26933,79136,00837,36418,83617,65624,78727,35630,46730,35035,48736,47735,22437,355
  Inventory-----------------3515064901,0491,036
  Net PPE-4.9%80885090274275869066265255255438128922.00---7581,5941,8321,9462,236
Liabilities-9.2%2,7052,9804,9842,7902,9042,8923,0873,8022,7751,7487219931,2661,5381,8102,3586,6987,3124,3254,0103,755
  Current Liabilities-9.6%1,6001,7703,6711,3761,3891,2821,3832,0061,6759647218296588351,8102,3583,1223,5383,7373,4103,291
Shareholder's Equity-28.2%8,45611,77615,32922,28925,00627,65430,20931,29334,20637,33039,19620,75219,98624,78626,63128,95431,07336,13936,29835,67538,870
  Retained Earnings-1.2%-333,000-329,026-324,998-317,539-314,300-310,954-307,739-305,800-302,300-298,800-296,291-293,695-291,184-282,234-279,465-276,742-273,372-267,078-260,755-253,772-247,373
  Additional Paid-In Capital0.2%341,467340,792340,317339,817339,273338,600337,940337,113336,526336,145335,479314,441311,164306,889306,089305,566304,315303,087296,929289,329286,128
Shares Outstanding0.0%8,7198,7188,7178,7158,7138,7118,7118,7068,7058,6978,6706,6526,5656,5296,5286,4626,5186,3436,2015,8135,700
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations40.0%-3,189,000-5,311,000-4,733,000-3,075,000-2,186,000-2,414,000-1,541,000-3,356,000-2,143,000-1,413,000-2,114,000-1,491,000-7,148,000-2,570,000-3,209,000-583,000-5,155,000-5,935,000-5,077,000-3,952,000-4,324,000
  Share Based Compensation42.1%675,000475,000500,000544,000673,000660,000827,000588,000426,000415,000287,000206,0004,138,000925,000400,0001,252,0001,236,0001,220,0001,282,0001,358,0001,274,000
Cashflow From Investing-98.4%12,000764,000-162,0009,975,000-86,000-10,693,000-53,000-133,000-29,000-194,000-111,000-289,0005,0002,00019,000701,00026,0001,000-42,000-25,000-11,000
Cashflow From Financing---------1,000-45,000251,00020,753,0003,071,00012,000-1,000--1,000-8,0004,944,0006,324,0001,846,0002,077,000
  Buy Backs----------------------

ONVO Income Statement

2023-09-30
Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues    
Total Revenues$ 0$ 77$ 75$ 77
Revenue From Contract With Customer Product And Service [Extensible List]us-gaap:RoyaltyMemberus-gaap:RoyaltyMemberus-gaap:RoyaltyMemberus-gaap:RoyaltyMember
Research and development expenses$ 1,335$ 1,231$ 3,001$ 2,251
Selling, general and administrative expenses2,7802,2005,3844,419
Total costs and expenses4,1153,4318,3856,670
Loss from Operations(4,115)(3,354)(8,310)(6,593)
Other Income (Expense)    
(Loss) gain on investment in equity securities0(70)12(75)
Interest income121103278134
Total Other Income1213329059
Income Tax Expense00(2)(2)
Net Loss(3,994)(3,321)(8,022)(6,536)
Other Comprehensive Loss:    
Unrealized loss on available-for-sale debt securities(1)0(1)0
Comprehensive loss$ (3,995)$ (3,321)$ (8,023)$ (6,536)
Net loss per common share basic$ (0.46)$ (0.38)$ (0.92)$ (0.75)
Net loss per common share diluted$ (0.46)$ (0.38)$ (0.92)$ (0.75)
Weighted average shares used in computing net loss per common share basic8,718,5028,712,2848,717,8708,711,630
Weighted average shares used in computing net loss per common share diluted8,718,5028,712,2848,717,8708,711,630

ONVO Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Mar. 31, 2023
Current Assets  
Cash and cash equivalents$ 7,617$ 15,301
Accounts receivable55152
Investment in equity securities0706
Prepaid expenses and other current assets624889
Total current assets8,29617,048
Fixed assets, net808902
Restricted cash143143
Operating lease right-of-use assets1,5051,705
Prepaid expenses and other assets, net409515
Total assets11,16120,313
Current Liabilities  
Accounts payable435331
Accrued expenses6662,848
Operating lease liability, current portion499492
Total current liabilities1,6003,671
Operating lease liability, net of current portion1,1051,313
Total liabilities2,7054,984
Commitments and Contingencies (Note 7)
Stockholders’ Equity  
Common stock, $0.001 par value; 200,000,000 shares authorized, 8,719,453 and 8,716,906 shares issued and outstanding at September 30, 2023 and March 31, 2023, respectively99
Additional paid-in capital341,467340,317
Accumulated deficit(333,020)(324,998)
Accumulated other comprehensive income12
Treasury stock, 46 shares at cost(1)(1)
Total stockholders’ equity8,45615,329
Total Liabilities and Stockholders’ Equity$ 11,161$ 20,313

About Organovo Holdings Inc

ONVO
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.
 WEBSITEwww.organovo.com
 EMPLOYEES23

Organovo Holdings Inc Frequently Asked Questions

What is the ticker symbol for Organovo Holdings Inc?

Ticker symbol for Organovo Holdings Inc is ONVO.

What is the market capital of Organovo Holdings Inc (ONVO)?

As of Mon Nov 27 2023, market cap of Organovo Holdings Inc is 10.29 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ONVO stock?

You can check ONVO's fair value in chart. The fair value of Organovo Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Organovo Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ONVO so that you know how good or bad the model has been in the past so you can discard it if needed.

Is Organovo Holdings Inc stock overpriced or underpriced?

The fair value guage provides a quick view whether ONVO is over valued or under valued. Whether Organovo Holdings Inc is cheap or expensive depends on the assumptions which impact Organovo Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ONVO.

What is Organovo Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Nov 27 2023, ONVO's PE ratio (Price to Earnings) is -0.55 and Price to Sales (PS) ratio is 27.96. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ONVO PE ratio will change depending on the future growth rate expectations of investors.